Willard Dere
Director/Board Member bij BIOMARIN PHARMACEUTICAL INC.
Vermogen: 3 M $ op 31-03-2024
Profiel
Willard H.
Dere is currently serving as an Independent Director at BioMarin Pharmaceutical, Inc., Mersana Therapeutics, Inc., and Seres Therapeutics, Inc. He is also a Professor and Executive Director of Personalized Health at The University of Utah Health Sciences Center.
Additionally, he holds positions as a Director at Peel Therapeutics, Inc., Metagenomi, Inc., and Angitia Biopharmaceuticals Guangzhou Ltd.
Dr. Dere previously served as an Independent Director at Radius Health, Inc. and OCERA Therapeutics LLC.
He also held positions at Clinical & Translational Science Institute, Metagenomi Technologies LLC, Amgen, Inc., Eli Lilly & Co., and The Indiana University School of Medicine.
Dr. Dere's educational background includes an undergraduate degree and a doctorate from the University of California, Davis.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 23-05-2023 | 27 580 ( 0.01% ) | 2 M $ | 31-03-2024 | |
METAGENOMI, INC.
0.14% | 01-04-2024 | 51 275 ( 0.14% ) | 540 951 $ | 31-03-2024 |
| 02-01-2024 | 39 182 ( 0.03% ) | 175 535 $ | 31-03-2024 | |
SERES THERAPEUTICS INC
0.02% | 04-04-2024 | 31 746 ( 0.02% ) | 24 571 $ | 31-03-2024 |
Actieve functies van Willard Dere
| Bedrijven | Functie | Begin |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Director/Board Member | 18-07-2016 |
| SERES THERAPEUTICS, INC. | Director/Board Member | 11-07-2017 |
| MERSANA THERAPEUTICS, INC. | Director/Board Member | 19-03-2018 |
| METAGENOMI, INC. | Director/Board Member | 01-08-2021 |
| The University of Utah Health Sciences Center | Corporate Officer/Principal | 01-11-2014 |
Peel Therapeutics, Inc.
 Peel Therapeutics, Inc. BiotechnologyHealth Technology Peel Therapeutics, Inc. engages as pre-clinical stage biotech that is strategically positioned at the intersection of nature and technology. The company is founded by Joshua Schiffman and Avi Schroeder in 2015 and is headquartered in Salt Lake City, UT. | Director/Board Member | - |
Angitia Biopharmaceuticals Guangzhou Ltd.
 Angitia Biopharmaceuticals Guangzhou Ltd. BiotechnologyHealth Technology Angitia Biopharmaceuticals Guangzhou Ltd. develops therapies for musculoskeletal diseases. The company is based in Guangzhou, China. The Chinese company was founded in 2018 by Muyu Li, Hua Zhu Ke. Hua Zhu Ke has been the CEO since 2018. | Chief Tech/Sci/R&D Officer | 01-07-2022 |
Eerdere bekende functies van Willard Dere
| Bedrijven | Functie | Einde |
|---|---|---|
| RADIUS HEALTH, INC. | Director/Board Member | 15-08-2022 |
| OCERA THERAPEUTICS INC | Director/Board Member | 11-12-2017 |
| ░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░ ░░░░░░░░░░ ░░░░░░ ░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░ ░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Willard Dere
| University of California, Davis | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 6 |
|---|---|
| AMGEN INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| MERSANA THERAPEUTICS, INC. | Health Technology |
| SERES THERAPEUTICS, INC. | Health Technology |
| METAGENOMI, INC. | Health Technology |
| Bedrijven in privébezit | 8 |
|---|---|
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Ocera Therapeutics, Inc.
 Ocera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ocera Therapeutics, Inc. manufactures pharmaceuticals products. The company was founded in 2004 and is headquartered in Hazelwood, MO. | Health Technology |
| The University of Utah Health Sciences Center | |
Clinical & Translational Science Institute
 Clinical & Translational Science Institute Engineering & ConstructionIndustrial Services The Clinical & Translational Science Institute at the University of Pittsburgh is an organization dedicated to advancing medical research and improving patient care. The private company is based in Pittsburgh, PA. The institute's official website provides information about its mission and initiatives. | Industrial Services |
Peel Therapeutics, Inc.
Peel Therapeutics, Inc. BiotechnologyHealth Technology Peel Therapeutics, Inc. engages as pre-clinical stage biotech that is strategically positioned at the intersection of nature and technology. The company is founded by Joshua Schiffman and Avi Schroeder in 2015 and is headquartered in Salt Lake City, UT. | Health Technology |
Metagenomi Technologies LLC
 Metagenomi Technologies LLC BiotechnologyHealth Technology Metagenomi Technologies LLC engages in the development of curative therapeutics and gene-editing technologies and therapies. The company was founded by Brian C. Thomas in September 2016 and is headquartered in Emeryville, CA. | Health Technology |
Angitia Biopharmaceuticals Guangzhou Ltd.
Angitia Biopharmaceuticals Guangzhou Ltd. BiotechnologyHealth Technology Angitia Biopharmaceuticals Guangzhou Ltd. develops therapies for musculoskeletal diseases. The company is based in Guangzhou, China. The Chinese company was founded in 2018 by Muyu Li, Hua Zhu Ke. Hua Zhu Ke has been the CEO since 2018. | Health Technology |
| Center for Genomic Medicine Massachusetts General Hospital |
